EP1624863A1 - Verbesserungen einer anti-aromatase-zusammensetzung oder im zusammenhang damit - Google Patents

Verbesserungen einer anti-aromatase-zusammensetzung oder im zusammenhang damit

Info

Publication number
EP1624863A1
EP1624863A1 EP03702128A EP03702128A EP1624863A1 EP 1624863 A1 EP1624863 A1 EP 1624863A1 EP 03702128 A EP03702128 A EP 03702128A EP 03702128 A EP03702128 A EP 03702128A EP 1624863 A1 EP1624863 A1 EP 1624863A1
Authority
EP
European Patent Office
Prior art keywords
range
aromatase
dose
capsule
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03702128A
Other languages
English (en)
French (fr)
Inventor
Michael Farley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1624863A1 publication Critical patent/EP1624863A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond

Definitions

  • This testosterone/ estrone ratio will exert a powerful and considerable reactions to the emotional well being, as well as in sexual functions, libido, muscle mass and strength, energy, cardiovascular health, bone integrity and memory behavior.
  • testosterone/ estrogen ratio is directly influenced by the aromitazation and bioavailable levels of several other hormones, including DHEA projesterone, androstenedione, estrone aldosterone, cortisol, estradiol and dihydrotestoasterone.
  • DHEA projesterone androstenedione
  • estrone aldosterone cortisol
  • estradiol estradiol
  • dihydrotestoasterone dihydrotestoasterone.
  • These hormones which directly effect testosterone and estrogen ratios also directly effect emotional well being, as well as sexual function, libido, muscle mass, fat to lean muscle ratios, strength, energy, cardiovascular health, osteoporosis, memory and cognitive function, as well as risk for breast cancer and benign prostate hypertrophy. It is well established, that as a human being ages, these testosterone/ estrone ratios adjust and change with age, with increasing formation levels of estrone and a proportional decrease in the formation of testosterone.
  • the present invention includes an anti-aromatase pharmaceutical or more specifically a nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Uritica dioica) 16:1 in the range of about 275 mg. to about 350 mg; b: Pumpkin seed oil (cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to
  • the present invention also relates to a totally new use of a male hormone panel aromatasition structure with an androgen pathway as depicted at Table I and II, also for breast cancer and other related treatments. 10 TABLE I
  • Tables I and II depict Aromatisation structure that are beneficial to the method of treatment of various ailments, for example, benign prostate hyperfhrophy, some forms of breast cancer, and in the treatment of osteoporsis, etc.
  • the present invention relates to a totally new application of several naturally occurring aromatase inhibitors which interupt several stages in the presented hormone panel (Table I), which illustrates the currently accepted normal aromatization sequence.
  • This invention also incorporates for the first time, an inhibitor of sex hormone binding globulin which allows bioavailable hormone to remain active at target tissue sites for a longer period of time.
  • the present invention includes an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 g.; c.
  • this invention is an anti-aromatase capsule or dose in commpound form in which the pharmaceutical or nutraceutical composition consists of: a. Pumpkin seed oil (Cucubita pepo) of about 175 mg; b. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg.
  • this invention resides in an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Phgeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; c. Nettle root extract (Urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the pharmaceutical or nutraceutical composition consists of: a. Phgeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; c. Nettle root extract (Urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550
  • the present invention is an anti-aromatase capsule or dose in compound form comprising a formula in the pharmaceutical or nutraceutical composition of which each capsule or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (Urtica dioica) of about 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.
  • the invention resides in a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted by an anti-aromatase pharmaceutical or nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Urtica dioica) 16:1 in the range of about 275 mg. to above 350 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 g.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg.
  • the invention provides a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituted an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the invention assists a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituting an anti- aromatase capsule or dose compound form in which the composition for the maintenance of testosterone/ estrone ratios with the anti-aromatase composition being characterized by: . a pumpkin seed oil (cucubita pepo) of about 175 mg.; b. Nettle root extract (uritica dioica) 16:1 of about 300 mg.; c. Pygeum Africanum (prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 g.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the invention also includes a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted an anti-aromatase capsule or dose in compound form in which the pharmaceutical composition consists of: a. Pygeum Africanum (prunus africana) bark extract standardized to contain 13% total sterols and about 25 g.; b. Pumpkin seed oil (cucubita pepo) of about 175 mg.; c. Nettle root extract (urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the invention furthermore includes a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted by an anti-aromatase capsule or dose in compound form comprising a formula in the pharmaceutical composition of which each capsule or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (urtica dioica) of about 300 mg.; c. Pumpkin seed oil (cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.
  • An anti-aromatase pharmaceutical composition consisting of in capsule or dose to contain:
  • Nettle root extract (Urtica dioica) 16:1 in the range of about 275 to 350 mg.
  • Pumpkin seed oil (Cucubita pepo) in the range of about 150 to 205 mg.
  • Pygeum Africanum (Prunus africana) bark extract standardized to contain at least 12 to 15% of total sterols in the range of about 20 to 40 mg. and Chrysin in the range of 475 to 550 mg.
  • This pharmaceutical composition assists in the treatment of b enign prostate hyperthropy and breast cancer etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
EP03702128A 2003-01-13 2003-01-13 Verbesserungen einer anti-aromatase-zusammensetzung oder im zusammenhang damit Withdrawn EP1624863A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/001207 WO2004064814A1 (en) 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition

Publications (1)

Publication Number Publication Date
EP1624863A1 true EP1624863A1 (de) 2006-02-15

Family

ID=32769584

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03702128A Withdrawn EP1624863A1 (de) 2003-01-13 2003-01-13 Verbesserungen einer anti-aromatase-zusammensetzung oder im zusammenhang damit

Country Status (3)

Country Link
EP (1) EP1624863A1 (de)
AU (1) AU2003203012A1 (de)
WO (1) WO2004064814A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023161184A1 (en) * 2022-02-23 2023-08-31 Kevehazi Laura Mann Herbal composition for prostate health and prostate cancer prevention

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2034888B1 (es) * 1991-07-11 1994-02-16 Madaus Cerafarm Lab Procedimiento de obtencion de la fraccion acida total de los extractos lipidicos de los frutos del sabal serrulata.
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US6039950A (en) * 1995-04-14 2000-03-21 University Of Southern California Pharmaceutical grade saw palmetto
US20010008638A1 (en) * 1999-07-14 2001-07-19 Brian J. Wilding Nutritional supplement comprising at least one prohormone and at least one anti-estrogen compound in a time-release dosage form

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004064814A1 *

Also Published As

Publication number Publication date
WO2004064814A1 (en) 2004-08-05
AU2003203012A1 (en) 2004-08-13

Similar Documents

Publication Publication Date Title
Santos et al. Beyond tribulus (Tribulus terrestris L.): The effects of phytotherapics on testosterone, sperm and prostate parameters
Wankhede et al. Beneficial effects of fenugreek glycoside supplementation in male subjects during resistance training: a randomized controlled pilot study
Abd Jalil et al. Role of medicinal plants and natural products on osteoporotic fracture healing
Gonzales et al. Effects of different varieties of Maca (Lepidium meyenii) on bone structure in ovariectomized rats
US6346267B1 (en) Composition and method for treatment of symptoms associated with insufficient estrogen production
Kim Phytotherapy: emerging therapeutic option in urologic disease
Zand et al. Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression
Mayo Black cohosh and chasteberry: herbs valued by women for centuries
Ogunlakin et al. Ameliorative effect of Kigelia africana (Lam.) Benth. fruit methanol extract in letrozole-induced polycystic ovarian syndrome rat
US6607755B2 (en) Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
EP2705762B1 (de) Biologisch aktive nahrungsergänzung zur normalisierung des androgenspiegels bei männern und des gesamtzustandes sowie zur reduzierung von adipositas
EP1624863A1 (de) Verbesserungen einer anti-aromatase-zusammensetzung oder im zusammenhang damit
Mayo A natural approach to menopause
WO2004064813A1 (en) Improvements in or relating to anti-aromatase composition
WO2007141661A2 (en) Herbal compositions for the prevention or treatment of benign prostatic hyperplasia
George et al. Acceptance of herbal medicines in andrology
DE102014005513B4 (de) Mittel zur Prävention und Therapie von Tumorerkrankungen
Habib et al. Effect of Moringa Leaves and Seeds on Osteoporosis in Rats
Roeca et al. Menopause as a Manifestation of Aging
Kumari et al. New Emerging Aspect of Herbal Extracts for the Treatment of Osteoporosis: Overview
Geiselman et al. Nutritional Supplementation Approaches to Increase Testosterone Levels in Active Adult Males.
Stojanovska et al. The effect of complementary and alternative therapy at menopause: trick or treat
Chamawan et al. Effects of Pine Pollen Extract in Relieving Hot Flushes in Sex Hormone-Deficienct Rats
Djuidje et al. Effects of the Mixture of Erigeron floribundus (Asteraceae) and Tragia benthamii (Euphorbiaceae) on the Growth and Architecture of Estrogen-Sensitive Sexual Organs
Reena et al. Effect of Anabolic Steroid in Accelerating Healing Process of Experimentally Fractured Tibia of Rats and Compare its Fracture Healing Property with Terminalia arjuna

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080801